Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration
Daiichi Sankyo, Max Planck Innovation and LDC have signed an agreement providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at LDC.
LDC and SOTIO Enter License and Collaboration Agreement for First-in-class Cancer Metabolism Program
The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI) and SOTIO a.s. have signed a collaboration and license agreement providing SOTIO with exclusive rights to an oncology program addressing a novel target in tumor metabolism. It was discovered at the Max Planck Institute for Biology of Ageing and jointly advanced by the LDC and Max Planck scientists into drug discovery.
Arix Bioscience plc, LDC and University of Leeds collaborate to develop novel therapeutics for metabolic diseases
First project from LDC's agreement with Arix
Arix Bioscience plc (LSE:ARIX), a global healthcare and life science company supporting medical innovation, has signed an agreement with the Lead Discovery Center, Max Planck Innovation, and the University of Leeds to develop new therapeutics for metabolic diseases based on the discoveries from these organisations.
LDC and UGISense AG to Collaborate on New Drug Class
Lead Discovery Center GmbH (LDC) and the biotech company UGISense AG are about to initiate a collaboration to jointly develop innovative drugs using the proprietary UgimeresTM antisense platform.
LDC Teams up with Canadian McGill University in $1 Million Translational Drug Discovery Project
First research project to be funded under the Canada/Germany Program
Researchers from the Lead Discovery Center (LDC) in Dortmund, Germany led by Dr. Bert Klebl and McGill University in Montréal, Canada led by Dr. David Y. Thomas will work closely together to identify novel tools for protein trafficking and folding diseases drug discovery.The 3-years research initiative between LDCand McGill University will be funded for a total of $1M.
LDC and Boehringer Ingelheim Join Forces to Discover a Novel Approach for the Treatment of Schizophrenia
The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH and Boehringer Ingelheim International GmbH have signed an agreement providing Boehringer Ingelheim with the option to receive the exclusive rights to a new lead compound for the treatment of schizophrenia to be discovered and developed at the LDC.
LDC Enters new Industry Partnership for the Discovery of Novel Medicines
LDC and Roche will jointly advance innovative drug discovery projects
The Lead Discovery Center GmbH (LDC) and Roche will collaborate to identify and leverage innovative therapeutic opportunities that address diseases of unmet medical need across several disease areas.
news & press
Response to the structural transformation of the pharma industry [German only]
Bert Klebl, Peter Nussbaumer and Matthias Stein-Gerlach; transkript | Special Issue Kapital & Börse May 2009
Polishing Medical Rough Diamonds
Text: Marcus Anhäuser
Max Planck Society Magazine Special “Innovation” / 2009
Pages 47 – 53
Joint Initiative for Research and Innovation